Chris Sampson
Chris is an expert in economic evaluation. His research focuses on significant methodological and policy challenges relating to the value of interventions and programmes for health. At OHE, Chris’s research has addressed such policy-relevant issues as environmental sustainability, the adoption of digital therapeutics, cost-effectiveness thresholds, and the definition of quality-adjusted life years (QALYs).
His experience spans a diverse range of clinical contexts, including diabetes, oncology, sleep, and neonatal care, but his passion is for mental health; Chris is the Lead Convener for IHEA’s Mental Health Economics Special Interest Group. As a member of the EuroQol Group, Chris also conducts research on the EQ-5D, focusing on the development of ‘bolt-on’ items.
Chris is a leading organiser in the international health economics community; he is the founder and Editor-in-chief of The Academic Health Economists’ Blog and webmaster for the UK’s Health Economists’ Study Group (HESG).
Chris joined OHE in 2017. Prior to this he worked as a health economist for the University of Nottingham, where he also obtained his PhD. He has a BA in Economics and an MSc in Economics & Health Economics from the University of Sheffield.
Publications and Insights
- Insight: Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
- Insight: Infectious disease: another reason to try Veganuary for the NHS
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Insight: Around the World in HTAs: United States – Making HTA Great Again
- Insight: Could Plant-based Diets Transform Health Care Spending?
- Publication: The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
- Insight: Sleepio: Lessons from the Frontier of Digital Therapeutics
- Insight: To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
- Publication: How is Quality of Life Measured for Health Technology Assessments?
- Publication: Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
- Publication: How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
- Publication: The Impact of New Medicines in the NHS: 70 Years of Innovation
- Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
- Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom